Evidence map›Paper›PMID 37049815›Full record

ReviewMolecules (Basel, Switzerland)2023

Localized Therapeutic Approaches Based on Micro/Nanofibers for Cancer Treatment.

Diana Alves, Joana C Araújo, Raul Fangueiro, Diana P Ferreira

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Diana AlvesCentre for Textile Science and Technology (2C2T), University of Minho, 4800 Guimarães, Portugal.ORCID 0000-0001-6489-8970
Joana C AraújoCentre for Textile Science and Technology (2C2T), University of Minho, 4800 Guimarães, Portugal.
Raul FangueiroCentre for Textile Science and Technology (2C2T), University of Minho, 4800 Guimarães, Portugal.ORCID 0000-0003-3303-6563
Diana P FerreiraCentre for Textile Science and Technology (2C2T), University of Minho, 4800 Guimarães, Portugal.ORCID 0000-0002-7862-4687

Funding

fct CEECIND/02803/2017
6 · The paper itself

Abstract

Cancer remains one of the most challenging health problems worldwide, and localized therapeutic approaches based on micro/nanofibers have shown potential for its treatment. Micro/nanofibers offer several advantages as a drug delivery system, such as high surface area, tunable pore size, and sustained release properties, which can improve drug efficacy and reduce side effects. In addition, functionalization of these fibers with nanoparticles can enhance their targeting and therapeutic capabilities. Localized delivery of drugs and/or other therapeutic agents via micro/nanofibers can also help to overcome the limitations of systemic administration, such as poor bioavailability and off-target effects. Several studies have shown promising results in preclinical models of cancer, including inhibition of tumor growth and improved survival rates. However, more research is needed to overcome technical and regulatory challenges to bring these approaches to clinical use. Localized therapeutic approaches based on micro/nanofibers hold great promise for the future of cancer treatment, providing a targeted, effective, and minimally invasive alternative to traditional treatments. The main focus of this review is to explore the current treatments utilizing micro/nanofibers, as well as localized drug delivery systems that rely on fibrous structures to deliver and release drugs for the treatment of cancer in a specific area.

Indexed as

NanofibersNeoplasmsDrug Delivery SystemsHumanscancerdrug delivery systemnanofibersnanoparticlestheragnostic

Identifiers

PMID37049815
PMCPMC10096407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.